ArticleScientific reports2022
Specific egg yolk antibody raised to biofilm associated protein (Bap) is protective against murine pneumonia caused by Acinetobacter baumannii.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.Archives of microbiology · 2026Review
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Therapeutic strategies against biofilm-associated multidrug-resistantFrontiers in microbiology · 2026Review
- OmpA virulence factor, a promising conserved vaccine candidate against Acinetobacter baumannii, could trigger autoreactive immune responses in susceptible population.BMC immunology · 2025Article
- A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade.Antibody therapeutics · 2025Review
- Recent advances in host models in studying virulence factors and pathogenesis ofFrontiers in cellular and infection microbiology · 2025Review
- A novel mRNA multi-epitope vaccine of Acinetobacter baumannii based on multi-target protein design in immunoinformatic approach.BMC genomics · 2024Article
- Respiratory tract infections: an update on the complexity of bacterial diversity, therapeutic interventions and breakthroughs.Archives of microbiology · 2024Review
- Production, characterization and therapeutic efficacy of egg yolk antibodies specific to Nosema ceranae.PloS one · 2024Article
- IgYs: on her majesty's secret service.Frontiers in immunology · 2023Review
- Non-antibiotic prevention and treatment againstFrontiers in microbiology · 2023Review
- IgY antibodies: The promising potential to overcome antibiotic resistance.Frontiers in immunology · 2023Review
- Subunit vaccines forFrontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii easily turns into pan drug-resistant (PDR) with a high mortality rate. No effective commercial antibiotic or approved vaccine is available against drug-resistant strains of this pathogen. Egg yolk immunoglobulin (IgY) could be used as a simple and low-cost biotherapeutic against its infections. This study evaluates the prophylactic potential of IgY against A. baumannii in a murine pneumonia model. White Leghorn hens were immunized with intramuscular injection of the recombinant biofilm-associated protein (Bap) from A. baumannii on days 0, 21, 42, and 63. The reactivity and antibiofilm activity of specific IgYs raised against the Bap was evaluated by indirect ELISA and a microtiter plate assay for biofilm formation. The IgYs against Bap were able to decrease the biofilm formation ability of A. baumannii and protect the mice against the challenge of A. baumannii. IgYs antibody raised here shows a good antigen-specificity and protectivity which can be used in passive immunotherapy against A. baumannii. In conclusion, the IgY against biofilm-associated protein proves prophylactic in a murine pneumonia model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.